An overview of myelodysplastic syndrome (MDS) and the role of biomarker testing in patients with the disorder.
Tamibarotene in Higher-Risk Myelodysplastic Syndrome (MDS)
Dr Gustavo Rivero talks about the significance of the RARA gene in patients with higher-risk MDS.
Dr Gustavo Rivero reviews the treatment options for patients with newly diagnosed higher-risk MDS and discusses tamibarotene’s recent orphan drug designation.
Gustavo Rivero, MD, comments on the ongoing SELECT-MDS-1 trial and as well as reviewing the adverse events of the potential combination of tamibarotene with azacitidine in patients with higher-risk MDS.
Dr Gustavo Rivero comments on novel treatment combinations and potential new biomarkers in patients with MDS.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5